Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer
| Autor: | Wonkyo Shin, Sang Yoon Park, Myong Cheol Lim, Byoung Gie Kim, Joseph J. Noh, Seung Hun Baek |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Indazoles Bevacizumab Newly diagnosed Carcinoma Ovarian Epithelial Poly(ADP-ribose) Polymerase Inhibitors Maintenance Chemotherapy Piperidines Internal medicine Republic of Korea Humans Medicine In patient Epithelial ovarian cancer Adverse effect Neoplasm Staging Retrospective Studies Dose Modification Ovarian Neoplasms Drug Tapering business.industry Medical record General Medicine Survival Analysis Treatment Outcome Chemotherapy Adjuvant Feasibility Studies Female Prospective research business medicine.drug |
| Zdroj: | Anticancer Research. 41:4603-4607 |
| ISSN: | 1791-7530 0250-7005 |
| Popis: | BACKGROUND/AIM Niraparib is effective against epithelial ovarian cancer (EOC), but with adverse effects. In this study, we retrospectively investigated niraparib maintenance treatment feasibility in Korean patients newly diagnosed with EOC. PATIENTS AND METHODS The medical records of 35 patients were reviewed. Data on the baseline clinical characteristics were collected, and adverse effects were described. RESULTS Sixteen patients underwent treatment suspension or dose reduction. There was no significant difference in adverse effects (A/E) due to the interval between adjuvant chemotherapy conclusion and niraparib initiation. The two groups had similar International Federation of Gynaecology and Obstetrics (FIGO) stages. The number of patients with a history of bevacizumab use was higher in the dose modification group than in the standard dose group. CONCLUSION Niraparib use must be considered in those previously treated with bevacizumab. There is a need for prospective research on lower dose ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|